MaxCyte Reports Third-Quarter 2026 Results, Updates Revenue Guidance
MaxCyte reported third-quarter 2026 financial results and updated its full-year 2026 total revenue guidance.
Story updates
11:07:07 AM UTC
SquawkNews
MaxCyte raised its 2026 total revenue guidance and said approximately 15% year-over-year core revenue growth is expected in the second half of 2026. The company also announced its intention to acquire Akron Bio.Material DetailsContext by AI AnalystThis is a mid-cycle update: management cites expect…
MaxCyte will host its third quarter 2026 earnings call today, November 10th, at 8:30 a.m. Eastern TimeThird Quarter and Recent Business Highlights:ROCKVILLE, Md., Nov. 10, 2026 (GLOBE NEWSWIRE) -- MaxCyte, Inc. NASDAQ:MXCT, a leading cell-engineering company providing enabling platform technologies…